Brokerages Set Zynerba Pharmaceuticals Inc (ZYNE) PT at $17.56
Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) have earned an average rating of “Hold” from the fourteen brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $17.56.
ZYNE has been the topic of several research reports. Seaport Global Securities reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, March 13th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 13th. Cantor Fitzgerald set a $20.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 12th. Ladenburg Thalmann began coverage on Zynerba Pharmaceuticals in a research report on Monday, January 29th. They set a “buy” rating and a $25.50 price target on the stock. Finally, Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Thursday, March 15th.
In related news, major shareholder Michael Rapp purchased 15,000 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Wednesday, May 2nd. The shares were acquired at an average price of $10.46 per share, with a total value of $156,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 12.67% of the company’s stock.
Zynerba Pharmaceuticals stock opened at $10.14 on Thursday. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $20.73.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Tuesday, May 8th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.23). equities analysts predict that Zynerba Pharmaceuticals will post -2.99 EPS for the current year.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.